Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.70 | N/A | -7.57% |
management commentary, guidance changes, and full analysis available with Pro.
| -7.57% |
Tone: Defensive
Overall, management expressed caution regarding current market conditions. They highlighted the importance of maintaining a steady course amid uncertainties.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term growth despite short-term hurdles.
Amgen's earnings report shows a slight miss on EPS, which may raise concerns among investors about the company's short-term performance. The stock reacted with a minor decline of 0.15%, indicating a muted response from the market. Management's defensive tone suggests they are aware of the challenges ahead but remain focused on long-term strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CADENCE DESIGN SYS I
Apr 26, 2021